Douglas K - Search Results

1

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. Among authors: douglas k. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.

2

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Licht C, et al. Among authors: douglas k. Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4. Kidney Int. 2015. PMID: 25651368 Free PMC article. Clinical Trial.

3

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.

Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, Clark A, Lester W, Gooding R, Biss T, Dutt T, Cooper N, Chapman O, Cranfield T, Douglas K, Watson HG, van Veen JJ, Sibson K, Thomas W, Manson L, Hill QA, Benjamin S, Ellis D, Westwood JP, Thomas M, Scully M. Alwan F, et al. Among authors: douglas k. Blood. 2017 Jul 27;130(4):466-471. doi: 10.1182/blood-2016-12-758656. Epub 2017 Jun 2. Blood. 2017. PMID: 28576877 Free article. Clinical Trial.

4

Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019.

HaemSTAR Collaborators. HaemSTAR Collaborators. J Thromb Haemost. 2022 Jun;20(6):1428-1436. doi: 10.1111/jth.15681. Epub 2022 Mar 11. J Thromb Haemost. 2022. PMID: 35189012 Free PMC article.

5

Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads.

Austin SE, Khan MO, Douglas KT. Austin SE, et al. Among authors: douglas kt. Drug Des Discov. 1999 Jul;16(1):5-23. Drug Des Discov. 1999. PMID: 10466053 Review.

6

Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines.

Khan MO, Austin SE, Chan C, Yin H, Marks D, Vaghjiani SN, Kendrick H, Yardley V, Croft SL, Douglas KT. Khan MO, et al. Among authors: douglas kt. J Med Chem. 2000 Aug 10;43(16):3148-56. doi: 10.1021/jm000156+. J Med Chem. 2000. PMID: 10956223

7

Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide.

Parveen S, Khan MO, Austin SE, Croft SL, Yardley V, Rock P, Douglas KT. Parveen S, et al. J Med Chem. 2005 Dec 15;48(25):8087-97. doi: 10.1021/jm050819t. J Med Chem. 2005. PMID: 16335933

8

Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks.

McKie JH, Garforth J, Jaouhari R, Chan C, Yin H, Besheya T, Fairlamb AH, Douglas KT. McKie JH, et al. Among authors: douglas kt. Amino Acids. 2001;20(2):145-53. doi: 10.1007/s007260170055. Amino Acids. 2001. PMID: 11332449

9

Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine.

Garforth J, Yin H, McKie JH, Douglas KT, Fairlamb AH. Garforth J, et al. Among authors: douglas kt. J Enzyme Inhib. 1997 Aug;12(3):161-73. doi: 10.3109/14756369709029312. J Enzyme Inhib. 1997. PMID: 9314113

10

Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures.

Benson TJ, McKie JH, Garforth J, Borges A, Fairlamb AH, Douglas KT. Benson TJ, et al. Among authors: douglas kt. Biochem J. 1992 Aug 15;286 ( Pt 1)(Pt 1):9-11. doi: 10.1042/bj2860009. Biochem J. 1992. PMID: 1355650 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

882 results

Search Page